Loading…
Lobbying Spend
—
Filings
132
Firms Hired
3
Active Period
2010–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Lower Costs, More Cures Act of 2021
2021 · fourth_quarter · Firm: W STRATEGIES, LLC
21st Century Cures 2.0. H.R.5376: Build Back Better Act as it relates to H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, H.R.19. Lower Costs, More Cures Act of 2021 and Orphan Drug Tax Credit.
Client expense: — · Firm income: $60,000
Matched citations: H.R.19
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: W STRATEGIES, LLC
21st Century Cures 2.0. H.R.5376: Build Back Better Act as it relates to H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, H.R.19. Lower Costs, More Cures Act of 2021 and Orphan Drug Tax Credit.
Client expense: — · Firm income: $60,000
Matched citations: H.R.3
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: W STRATEGIES, LLC
21st Century Cures 2.0. H.R.5376: Build Back Better Act as it relates to H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, H.R.19. Lower Costs, More Cures Act of 2021 and Orphan Drug Tax Credit.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5376
Orphan Drug Tax Credit provisions in the Build Back Better Act (H.R. 5376).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Orphan Drug Tax Credit provisions in the Build Back Better (H.R. 5376).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Lower Costs, More Cures Act of 2021
2021 · third_quarter · Firm: W STRATEGIES, LLC
21st Century Cures 2.0. FY 22 Budget Reconciliation as it relates to H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, H.R.19: Lower Costs, More Cures Act of 2021 and the Orphan Drug Tax Credit.
Client expense: — · Firm income: $60,000
Matched citations: H.R.19
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: W STRATEGIES, LLC
21st Century Cures 2.0. FY 22 Budget Reconciliation as it relates to H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, H.R.19: Lower Costs, More Cures Act of 2021 and the Orphan Drug Tax Credit.
Client expense: — · Firm income: $60,000
Matched citations: H.R.3
Lower Costs, More Cures Act of 2021
2021 · second_quarter · Firm: W STRATEGIES, LLC
Education around access issues for rare therapies in the inpatient setting. ICD diagnosis codes for rare disease. 21st Century Cures 2.0. H.R.3: Elijah E. Cummings Lower Drug Costs Now Act. H.R.19: Lower Costs, More Cures Act of 2021.
Client expense: — · Firm income: $60,000
Matched citations: H.R.19
Elijah E. Cummings Lower Drug Costs Now Act
2021 · second_quarter · Firm: W STRATEGIES, LLC
Education around access issues for rare therapies in the inpatient setting. ICD diagnosis codes for rare disease. 21st Century Cures 2.0. H.R.3: Elijah E. Cummings Lower Drug Costs Now Act. H.R.19: Lower Costs, More Cures Act of 2021.
Client expense: — · Firm income: $60,000
Matched citations: H.R.3
American Rescue Plan Act of 2021
2021 · first_quarter · Firm: W STRATEGIES, LLC
Education around access issues for rare therapies in the inpatient setting. H.R.1319 - American Rescue Plan Act of 2021.
Client expense: — · Firm income: $60,000
Matched citations: H.R.1319
Consolidated Appropriations Act, 2021
2020 · fourth_quarter · Firm: W STRATEGIES, LLC
CMS IPPS rule as it relates to the NTAP program. H.R.133: Consolidated Appropriations Act, 2021. Administration Executive Order and Rulemaking in International Drug Pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R.133
Creating Hope Reauthorization Act
2020 · third_quarter · Firm: THE KPM GROUP DC LLC
S.4010 - Creating Hope Reauthorization Act
Client expense: — · Firm income: $50,000
Matched citations: S.4010
Patient Protection and Affordable Care Enhancement Act
2020 · second_quarter · Firm: W STRATEGIES, LLC
H.R.1425: Patient Protection and Affordable Care Enhancement Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R.1425
Protecting Consumer Access to Generic Drugs Act of 2019
2020 · second_quarter · Firm: NVG, LLC
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1499
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: H.R.2374
Preserve Access to Affordable Generics and Biosimilars Act
2020 · second_quarter · Firm: NVG, LLC
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: H.R.2375
To Offer Refugees College Help (TORCH) Act
2020 · second_quarter · Firm: NVG, LLC
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3391
Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
2020 · second_quarter · Firm: NVG, LLC
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4398
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: H.R.965
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: S.1224
Affordable Prescriptions for Patients Act of 2019
2020 · second_quarter · Firm: NVG, LLC
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: S.1416
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2020 · second_quarter · Firm: NVG, LLC
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: S.340
Preserve Access to Affordable Generics and Biosimilars Act
2020 · second_quarter · Firm: NVG, LLC
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: S.64
Protecting Consumer Access to Generic Drugs Act of 2019
2020 · first_quarter · Firm: NVG, LLC
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1499
Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3391); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).
Client expense: — · Firm income: $60,000
Matched citations: H.R.2374
Source: Senate LDA